What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Fortunato Ciardiello mainly investigates Internal medicine, Cancer research, Epidermal growth factor receptor, Oncology and Cetuximab.
The study incorporates disciplines such as Endocrinology and Surgery in addition to Internal medicine.
His research integrates issues of Epidermal growth factor, Growth factor receptor inhibitor, Growth factor receptor, Autocrine signalling and EGFR inhibitors in his study of Cancer research.
His Epidermal growth factor receptor research incorporates themes from Cancer cell, Tyrosine kinase, Angiogenesis and Pharmacology.
Fortunato Ciardiello interconnects Hazard ratio, Bevacizumab and Clinical trial, Pathology in the investigation of issues within Oncology.
His Cetuximab research is multidisciplinary, relying on both Pharmacokinetics, Irinotecan, FOLFIRI and Transplantation.
His most cited work include:
- Epidermal growth factor-related peptides and their receptors in human malignancies (2398 citations)
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2085 citations)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis (1560 citations)
What are the main themes of his work throughout his whole career to date?
Fortunato Ciardiello mainly focuses on Internal medicine, Oncology, Cancer research, Colorectal cancer and Cetuximab.
His Internal medicine course of study focuses on Surgery and Gastroenterology.
His work on Erlotinib as part of general Oncology study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His study in Cancer research is interdisciplinary in nature, drawing from both Epidermal growth factor, Cell growth, Epidermal growth factor receptor, Cancer cell and Tyrosine kinase.
His Colorectal cancer research is multidisciplinary, incorporating elements of Bevacizumab, Binimetinib and Monoclonal antibody.
His Cetuximab study combines topics from a wide range of disciplines, such as Irinotecan and FOLFIRI.
He most often published in these fields:
- Internal medicine (51.04%)
- Oncology (41.10%)
- Cancer research (32.27%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (51.04%)
- Oncology (41.10%)
- Colorectal cancer (29.94%)
In recent papers he was focusing on the following fields of study:
Fortunato Ciardiello mostly deals with Internal medicine, Oncology, Colorectal cancer, Cancer research and Cetuximab.
His study in Chemotherapy, Cancer, Clinical trial, Regorafenib and Phases of clinical research falls within the category of Internal medicine.
His Oncology research focuses on Randomized controlled trial and how it relates to Hazard ratio.
His work deals with themes such as Binimetinib and Trastuzumab, which intersect with Colorectal cancer.
His Cancer research research integrates issues from Cell culture, Epidermal growth factor receptor, Cancer cell, Immune system and PI3K/AKT/mTOR pathway.
The Cetuximab study combines topics in areas such as Avelumab, Wild type and FOLFIRI.
Between 2016 and 2021, his most popular works were:
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2085 citations)
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. (349 citations)
- Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer Retrospective Analyses of the CRYSTAL and FIRE-3 Trials (346 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Oncology, Colorectal cancer, Cancer research and Cetuximab.
He combines subjects such as Biomarker, Clinical trial and Docetaxel with his study of Oncology.
Fortunato Ciardiello has included themes like Binimetinib and Disease in his Colorectal cancer study.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cancer, Carcinogenesis, Immunotherapy and Receptor tyrosine kinase.
His Cetuximab study combines topics in areas such as MAPK/ERK pathway and FOLFIRI.
His research integrates issues of Angiogenesis and Epidermal growth factor receptor in his study of Lung cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
